Abiomed (NSDQ:ABMD) topped the consensus forecast for its fiscal third-quarter results despite taking a nearly $19 million hit due to the tax reforms enacted last year.

The Danvers, Mass.-based cardiac assist device maker posted profits of $13.4 million, or 29¢ per share, on sales of $154.0 million for the three months ended Dec. 31, 2017, for a bottom-line slide of -12.9% on sales growth of 34.3%.

But excluding the $18.8 million tax reform hit, adjusted earnings per share were 70¢, 19¢ ahead of Wall Street, where analysts were looking for sales of $148.5 million.

“It is an exciting time for the company as we collaborate with our customers to improve patient outcomes and the standard of care for circulatory support,” chairman, president & CEO Michael Minogue said in prepared remarks. “The field of heart recovery is growing and Abiomed is well-positioned to capture the $5 billion U.S. market opportunity, while planting the seeds for future growth in global markets.”

Abiomed raised its top-line outlook to $583 million, up from prior guidance for $565 million to $575 million, which works out to a $164 million projection for fiscal Q4.

ABMD shares were up 1.3% to $238.00 apiece today in pre-market trading.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW